CervoMed completes enrollment in Phase 2a neflamapimod trial for nonfluent PPA

CervoMed Inc.

CervoMed Inc.

CRVO

0.00
  • CervoMed completed enrollment in a Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia, a form of frontotemporal dementia.
  • Trial enrolled 25 participants on oral dosing for 24 weeks, followed by a 12-week randomized, double-blind, placebo-controlled extension.
  • Interim biomarker data slated for presentation at the CTAD conference in November 2026; first biomarker readout expected early Q4 2026.
  • First clinical data expected in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.